Category Business

Lilly’s Q1 2024 Financials: Boosts Full-Year Revenue Projection by $2B, Highlights Pipeline Momentum

Eli Lilly and Company (NYSE: LLY) unveiled its financial performance for the first quarter of 2024 today. David A. Ricks, Lilly’s chair and CEO, commented on the company’s robust year-over-year revenue growth, attributing it to strong sales of Mounjaro and…

Read MoreLilly’s Q1 2024 Financials: Boosts Full-Year Revenue Projection by $2B, Highlights Pipeline Momentum

Amgen Prepares to Present Marketing Authorization Application for Teprotumumab to the European Medicines Agency

Amgen (NASDAQ:AMGN) has announced its forthcoming submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab. Teprotumumab, a fully human monoclonal antibody and targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R), is aimed at…

Read MoreAmgen Prepares to Present Marketing Authorization Application for Teprotumumab to the European Medicines Agency

ATS Presentation: Sanofi’s Innovations in Immune-Mediated Respiratory Therapies

The American Thoracic Society (ATS) International Conference, scheduled from May 17-22 in San Diego, will host the unveiling of twenty-five abstracts featuring both approved and investigational medicines from Sanofi. Among the highlights are presentations on Dupixent® (dupilumab), developed in collaboration…

Read MoreATS Presentation: Sanofi’s Innovations in Immune-Mediated Respiratory Therapies

CHMP Recommends Approval of Bristol Myers Squibb’s Opdivo® for First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma

Bristol Myers Squibb (NYSE: BMY) has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of Opdivo® (nivolumab) combined with cisplatin and gemcitabine as the first-line treatment for…

Read MoreCHMP Recommends Approval of Bristol Myers Squibb’s Opdivo® for First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma

EU Approves Vaidya as Additional Therapy for Adults with PNH and Persistent Haemolytic Anaemia Despite Rovelizumab or Eculizumab Treatment

Voydeya (danicopan) Receives EU Approval as Supplemental Treatment for Adults with PNH and Residual Hemolytic Anemia Voydeya (danicopan) has gained approval in the European Union (EU) to be used alongside ravulizumab or eculizumab for managing adult patients with paroxysmal nocturnal…

Read MoreEU Approves Vaidya as Additional Therapy for Adults with PNH and Persistent Haemolytic Anaemia Despite Rovelizumab or Eculizumab Treatment

FDA Grants Approval to Alecensa as the Primary Adjuvant Therapy for Individuals with ALK-Positive Early-Stage Non-Small Cell Lung Cancer

Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) has announced that the U.S. Food and Drug Administration (FDA) has given approval for Alecensa® (alectinib), an anaplastic lymphoma kinase (ALK) inhibitor, to be used as an adjuvant treatment subsequent to tumor resection for…

Read MoreFDA Grants Approval to Alecensa as the Primary Adjuvant Therapy for Individuals with ALK-Positive Early-Stage Non-Small Cell Lung Cancer

Revance Unveils Latest DAXXIFY® Findings at the 2024 American Academy of Neurology Annual Conference

Revance Therapeutics, Inc. (NASDAQ: RVNC) has unveiled significant insights into DAXXIFY® for the treatment of cervical dystonia at the American Academy of Neurology (AAN) annual meeting, running from April 13-18, 2024, in Denver, Colorado. The presentations, ASPEN-1 and ASPEN-OLS (open…

Read MoreRevance Unveils Latest DAXXIFY® Findings at the 2024 American Academy of Neurology Annual Conference